托伐普坦在急性心力衰竭伴容量超负荷患者中的短期效应
SECRET of CHF 双盲随机对照试验纳入 250 例急性心衰伴容量超负荷患者,比较托伐普坦 30 mg/日与安慰剂。第 1 天呼吸困难主要终点无差异,托伐普坦体重下降更明显;第 3 天托伐普坦呼吸困难改善更显著。
要点
- 托伐普坦 30 mg/日未改善第 1 天呼吸困难主要终点。
- 托伐普坦体重下降大于安慰剂(-2.4±2.1 kg vs -0.9±1.8 kg,p<0.001)。
- 第 3 天托伐普坦呼吸困难改善更显著(p=0.01)。
核心结论
- 在因急性心衰伴容量超负荷且被选为可能从血管加压素受体抑制中获益更多的患者中,托伐普坦虽快速且持续减重,但未带来更早的呼吸困难改善。
- 随后出现的呼吸困难差异值得进一步探索利尿与呼吸困难缓解的时间关系及托伐普坦可能的临床作用。
研究设计与样本
- 双盲随机对照试验,纳入 250 例患者,随机接受托伐普坦 30 mg/日或安慰剂。
- 入组条件:前 36 小时内住院、活动性呼吸困难,且满足以下任一:估算肾小球滤过率<60 ml/min/1.73 m2;低钠血症;或利尿剂抵抗(静脉呋塞米≥40 mg 后尿量≤125 ml/h)。
- 主要终点为采用新型标准化方法自评呼吸困难在第 8 小时和第 16 小时的 7 分制变化。
主要发现
- 第 1 天呼吸困难主要终点无差异。
- 托伐普坦体重下降大于安慰剂(-2.4±2.1 kg vs -0.9±1.8 kg;p<0.001)。
- 第 3 天托伐普坦呼吸困难改善更显著(p=0.01)。
- 2 项治疗与亚组交互作用显著:无颈静脉压升高和无腹水的患者相比于有这些体征的患者,主要终点方向偏向托伐普坦优于安慰剂。
关键数值与推荐
- 托伐普坦剂量为 30 mg/日。
- 利尿剂抵抗定义为静脉呋塞米≥40 mg 后尿量≤125 ml/h。
- 估算肾小球滤过率<60 ml/min/1.73 m2 为入组条件之一。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论提出随后出现的呼吸困难差异值得进一步探索利尿与呼吸困难缓解的时间关系及托伐普坦可能的临床作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with acute heart failure (AHF), dyspnea relief is the most immediate goal. Renal dysfunction, diuretic resistance, and hyponatremia represent treatment impediments. OBJECTIVES: It was hypothesized that the addition of tolvaptan to a background diuretic improved dyspnea early in patients selected for an enhanced vasopressin antagonism response. METHODS: In a double-blind trial, patients were randomized to tolvaptan 30 mg/day or placebo. Study entry required hospitalization within the previous 36 h, active dyspnea, and any of the following: 1) estimated glomerular filtration rate <60 ml/min/1.73 m2; 2) hyponatremia; or 3) diuretic resistance (urine output ≤125 ml/h following intravenous furosemide ≥40 mg). The primary endpoint was a 7-point change in self-assessed dyspnea at 8 and 16 h, using a novel standardized approach. RESULTS: We randomized 250 patients. There was no difference in the primary endpoint of day 1 dyspnea reduction, despite significantly greater weight reduction with tolvaptan (-2.4 ± 2.1 kg vs. -0.9 ± 1.8 kg; p < 0.001). At day 3, dyspnea reduction was greater with tolvaptan (p = 0.01). There were 2 significant treatment-by-subgroup interactions: patients without elevated jugular venous pressure and those without ascites showed directional favorability of tolvaptan over placebo for the primary endpoint compared with patients with these findings. CONCLUSIONS: Despite rapid and persistent weight loss with tolvaptan compared with placebo, in patients with AHF who were selected for greater potential benefit from vasopressin receptor inhibition, tolvaptan was not associated with greater early improvement in dyspnea. Apparent subsequent differences in dyspnea warrant further exploration of the temporal relationship between diuresis and dyspnea relief and a possible clinical role for tolvaptan. (Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management [SECRET of CHF]; NCT01584557).
引用
- Konstam MA, Kiernan M, Chandler A, et al. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload. J Am Coll Cardiol. 2017. PMID: 28302292. doi:10.1016/j.jacc.2016.12.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。